Craft

Onxeo

Stock Price

€0.7

2021-02-12

Market Capitalization

€53.7 M

2021-02-12

Revenue

€1.4 M

FY, 2022

Onxeo Summary

Company Summary

Overview
Onxeo is a biotechnology company, that develops drugs for the treatment of orphan oncology diseases worldwide. The Company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops Beleodaq for the treatment of others liquid or solid tumors; AsiDNA, which is in Phase I clinical trial for the treatment of metastatic melanoma; Livatag that is in Phase III clinical trial to treat advanced primary liver cancer; and Validive, which is in Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer.
Type
Public
Status
Active
Founded
1997
HQ
Paris, FR | view all locations
Website
http://www.onxeo.com/en/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Nicolas Trebouta

    Nicolas Trebouta, Director

    • Nicolas Fellmann

      Nicolas Fellmann, Chief Financial Officer

    • Bryan Giraudo

      Bryan Giraudo, Independent Director

      • Audrey Legentil-Dumery

        Audrey Legentil-Dumery, Director of Human Resources

      LocationsView all

      2 locations detected

      • Paris, IDF HQ

        France

        49 Bd du Général Martial Valin

      • New York, NY

        United States

        315 Madison Ave #3006

      Onxeo Financials

      Summary Financials

      Gross profit (H1, 2023)
      €508.0K
      Net income (H1, 2023)
      (€11.6M)
      Cash (H1, 2023)
      €16.8M
      EBIT (H1, 2023)
      (€11.6M)
      Enterprise value
      $46.4M

      Footer menu